Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 5/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.44 |
| ▸ | IGF1R | P08069 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11952788 | 0.92 | AURKA (0.50) | AURKARIPK1AURKBNTRK1IGF1R | |
| SCHEMBL11952787 | 0.92 | AURKA (0.50) | AURKARIPK1AURKBNTRK1IGF1R | |
| SCHEMBL11952793 | 0.91 | AURKA (0.45) | AURKARIPK1AURKBNTRK1IGF1R | |
| SCHEMBL11952795 | 0.88 | AURKA (0.52) | AURKARIPK1AURKBNTRK1IGF1R | |
| SCHEMBL11952797 | 0.88 | AURKA (0.46) | AURKARIPK1AURKBNTRK1IGF1R | |
| SCHEMBL11952798 | 0.88 | AURKA (0.47) | AURKARIPK1AURKBNTRK1IGF1R | |
| SCHEMBL11952792 | 0.88 | AURKA (0.49) | AURKARIPK1AURKBNTRK1IGF1R | |
| SCHEMBL11952791 | 0.88 | AURKA (0.51) | AURKARIPK1AURKBNTRK1IGF1R | |
| SCHEMBL11964288 | 0.86 | AURKA (0.56) | AURKARIPK1AURKBNTRK1KDM4E | |
| SCHEMBL11964167 | 0.86 | AURKA (0.48) | AURKARIPK1AURKBNTRK1IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9078902-B2 | Triazine derivatives and their therapeutical applications | NANTBIOSCIENCE, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20120196860-A1 | Triazine derivatives and their therapeutical applications | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-08-02 | — | — | US | disclosed |
| WO-2010144550-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | ABRAXIS BIOSCIENCE, LLC (US) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196860-A1 | Triazine derivatives and their therapeutical applications | MAP3K2, MAP3K5, MAP4K2 | AURKA 877/4885RIPK1 367/4885AURKB 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.